Joana Vindeirinho, PhD,  —

Joana is a Science Writer at BioNews. She is a cell biologist with a PhD in neurobiology of disease (University of Coimbra, Portugal), focused on the role of the adenosinergic system in the early stages of diabetic retinopathy. She moved from research into high-impact medical editing in 2017, before shifting into a more direct science writing and communication role in 2022.

Articles by Joana Vindeirinho

AOC 1020 Now on FDA’s Fast Track as FSHD Treatment

The U.S. Food and Drug Administration (FDA) has given fast-track designation to AOC 1020, an investigational therapy for facioscapulohumeral muscular dystrophy (FSHD) developed by Avidity Biosciences. This designation allows more frequent interactions between a company and the regulatory agency, with the goal of speeding the development and review…

Entrada Selects Exon 45-skipping Therapy Candidate for DMD

Entrada Therapeutics has selected ENTR-601-45 as an investigational therapy candidate for people with Duchenne muscular dystrophy (DMD) who have mutations amenable to exon 45 skipping. The company is planning to file an Investigational New Drug application in the second half of 2024. These applications are used to request…